FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 413 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Targeting Inflammation Emerges as a Strategy for Treating Cancer August 19, 2022 Load more HOT NEWS College Basketball Star Plays First Game in Nearly Two Years After... Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer New chemotherapy-free treatment for bowel cancer made available in Scotland For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions
